<DOC>
	<DOCNO>NCT00555139</DOCNO>
	<brief_summary>To compare neuroimaging technique public speaking , way social anxiety patient respond administration GW876008 , GSK561679 , alprazolam placebo</brief_summary>
	<brief_title>A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<mesh_term>Anti-Anxiety Agents</mesh_term>
	<criteria>Inclusion criterion : Outpatient primary diagnosis Social Anxiety LSAS score 50 . Men woman 18 64 year age . Women include study reproductive toxicology data available time study start allow inclusion , accordance regulatory requirement . Body weight &gt; 50 kg BMI within range 18.5 31.0 kg/m2 . Capable give write informed consent , include compliance requirement restriction list consent form . The subject must able read , comprehend record information . A signed date write informed consent obtain subject . Subjects willing restrict alcohol intake 4 unit alcohol less per day . A unit equivalent 300 ml beer one measure spirit one glass wine . Women must non child bear potential commit consistent correct use acceptable method birth control must record source documentation screen verify continued compliance visit ; GSK acceptable contraceptive method , use consistently accordance product label instruction physician , follow : Subjects history peptic ulcer disease ( PUD ) know aetiology must provide documentation gastroenterologist aetiology PUD effective treatment provide full eradication ulcer symptom . Exclusion criterion : Any concomitant drug dose 24 h dose . Any history clinically significant abnormality neurological system ( include dementia cognitive disorder significant head injury ) history seizure ( exclude febrile seizure ) . Subjects unstable medical disorder disorder would likely interfere action , absorption , distribution , metabolism excretion GW876008 , GSK561679 alprazolam , may pose safety concern , interfere accurate assessment safety . The subject current recent ( within six month ) document gastrointestinal disease Subject symptoms present illness well account another diagnosis subject meet DSMIV criterion Axis I disorder primary diagnosis currently within 6 month prior screen visit A current DSMIVTR diagnosis Antisocial Borderline Personality Disorder , Dementia , another current DSMIVTR Axis II diagnosis would suggest nonresponsiveness pharmacotherapy noncompliance protocol ; A current ( within six month prior Screening visit ) diagnosis anorexia nervosa bulimia ; Subjects history Schizophrenia , Schizoaffective Disorder , Bipolar Disorder . HAMD17 score great 15 . Subjects currently receive regularly schedule psychotherapy ( individual group , include cognitive behavioural therapy ) , plan initiate psychotherapy trial receive regularly schedule psychotherapy 12 week period prior Screening Visit . Subjects laboratory abnormality investigator 's judgment consider clinically significant resolve Randomization Visit . The subject semisupine systolic blood pressure le 90mmHg ( 85mmHg female ) great 140mmHg semisupine diastolic blood pressure le 45mmHg great 90mmHg ; pulse rate le 40bpm 90bpm . Women positive serum Human Chorionic Gonadotropin ( HCG ) pregnancy test screen visit , positive urine dipstick test Randomization , lactate plan become pregnant within next 2weeks Follow Up Visit . The subject participate clinical trial receive drug new chemical entity within 60 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Exposure four new chemical within 12 month prior first dose day . History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation . As result medical interview , physical examination screen investigation physician responsible considers subject unfit study . History long QT syndrome ( personal family ) cardiac conduction disorder , clinically significant cardiac disease . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John'sWort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator sponsor medication interfere study procedure compromise subject safety Subjects , opinion investigator , would noncompliant visit schedule study procedure ( e.g. , illiteracy , plan vacation , plan hospitalization study ) . Subjects euthyroid evidence normal TSH . Subjects maintain thyroid medication must euthyroid period least six month prior screen visit . Subject 's level FSH fall outside normal range Subjects diabetes high risk diabetes base documented history impair glucose tolerance . Subjects electrocardiographic ( ECG ) parameter outside Sponsorspecified range either screen randomization visit . Subjects electroconvulsive therapy ( ECT ) transcranial magnetic stimulation within 6 month prior Screening Visit . Subjects , lefthanded . The subject positive prestudy urine drug/ breath alcohol screen . A minimum list drug screen include Amphetamines , Barbiturates , Cocaine , Opiates , Cannabinoids Benzodiazepines . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Documented history hepatobiliary disease abnormality hepatic enzymesat screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>CRF-1 antagonist ,</keyword>
	<keyword>depression ,</keyword>
	<keyword>anxiety ,</keyword>
	<keyword>fMRI</keyword>
</DOC>